

18 / 19 June
Paris 2026



**Advances in
Multiple Sclerosis
& related disorders**
PROGRAM

Paris Brain Institute
Institut du cerveau - ICM
Hôpital de la Salpêtrière
PARIS - FRANCE

8H00 **Accueil**

9H00 **Introduction: France SEP and SFN representative**

SESSION 1 Positive and differential diagnosis of MS and related diseases

Chairs: Caroline Papeix (Paris, FR) and H el ene Z ephir (Lille, FR)

9H15 - 9H35 **Evolving MS diagnostic criteria: progress and challenges** | Christine Lebrun-Frenay
Nice, FR

9H35 - 9H55 **Contribution of new imaging sequences to the diagnosis of MS** | Marcello Moccia
Naples, IT

9H55 - 10H15 **Diagnostic pitfalls and complex cases** | Mar Tintore
Barcelona, ES

10H15 - 10H35 **NMOSD and MOGAD : updates on diagnostic criteria** | Romain Marignier
Lyon, FR

10H35 - 10H45 **General discussion**

10H45 - 11H15 **Coffee break in the exhibition room**

SESSION 2 Imaging MS pathophysiology: from neuropathology to clinical cohorts

Chairs: Benedetta Bodini (Paris, FR) and Adil Maarouf (Marseille, FR)

11H15 - 11H35 **Exploring the mechanisms of volumetric tissue changes** | Menno Schoonheim
Amsterdam, NL

11H35 - 11H55 **7T spinal cord MRI : advances, insights, and unmet needs** | Virginie Callot
Marseille, FR

11H55 - 12H15 **Imaging myelin content changes** | Cristina Granziera
Basel, CH

12H15 - 12H35 **Artificial intelligence in neuroimaging in MS** | Bruno Stankoff
Paris, FR

12H35 - 12H45 **General discussion**

12H45 - 13H45 **Lunch in the exhibition room & poster session**

13H45 - 14H45 **Industry Symposium**

SESSION 3 Therapy 1

Chairs: Sandra Vukusic (Lyon, FR) and Guillaume Mathey (Nancy, FR)

14H45 - 15H05 **New immunotherapies for MS**

Xavier Ayrygnac
Montpellier, FR

15H05 - 15H25 **Cellular therapies in MS**

Laure Michel
Rennes, FR

15H25 - 15H45 **Therapeutic strategies in NMOSD & MOGAD**

Alvaro Cobo-Calvo
Barcelona, ES

10H45 - 11H15 **Coffee break in the exhibition room**

SESSION 4 Therapy 2

Chairs: TBD and Elisabeth Maillart (Paris, FR)

16H15 - 16H35 **Fatigability in MS**

Peter Feys
Hasselt, BE

16H35 - 16H55 **Studying causality with observational data: target trial emulation**

Antoine Gavoille
Lyon, FR

16H55 - 17H15 **Adaptive trials and new designs**

Jeremy Chataway
London, UK

17H15 - 17H30 **General discussion**

17H30 - 18H30 **Industry Symposium**

18h30 **End of the day**

8H30 **Accueil**

9H00 **Introduction: France SEP and SFN representative**

SESSION 5 **Genetics and environment in MS and related diseases**
Chairs: David Laplaud (Nantes, FR) and Nicolas Collongues (Strasbourg, FR)

- 9H15 - 9H35 **Genetic susceptibility factors for MS and related diseases** Nicolas Vince
Nantes, FR
- 9H35 - 9H55 **Genetic susceptibility to MS severity: identification of new targets** Adil Harroud
Montreal, CA
- 9H55 - 10H15 **Non-infectious environmental factors in MS and potential interventions** Eric Thouvenot
Nîmes/Montpellier, FR
- 10H15 - 10H35 **The Role of Epstein-Barr Virus in MS: from pathogenesis to therapeutic potential** Marco Salvetti
Roma, IT

10H35 - 11H00 **Coffee break in the exhibition room**

SESSION 6 **Short oral communications**
Chair : Pierre-Olivier Courraud (Paris, FR)

11H00 - 12H00 6 short oral communications (10') selected by France SEP

12H00 - 12H45 **Keynote lecture** William Barrie
Cambridge, UK
 How did multiple sclerosis appear?

12H45 - 13H45 **Lunch in the exhibition room & poster session**

SESSION 7 **Immunological mechanisms of progression**
Chairs: Laure Michel (Rennes, FR) and Violetta Zujovic (Paris, FR)

- 14H15 - 14H35 **Tissue resident memory T cells and chronic CNS inflammation** Frederick Masson-
Toulouse, FR
- 14H35 - 14H55 **IL-2 and B-cell reprogramming** Céline Delaloy
Rennes, FR
- 14H55 - 15H15 **Cellular and transcriptomic signature of broad rim lesion** Tanja Kuhlmann
Münster, DE

SESSION 8 Remyelination and neuroprotection: from mechanisms to therapies

Chairs: Anne Desmazières (Paris, FR) et Maria-Cecilia Angulo (Paris, FR)

- | | | |
|---------------|--|--|
| 15H15 - 15H35 | Molecular targets for myelin and neuronal repair | Brahim Nait Oumesmar
<i>Paris, FR</i> |
| 15H35 - 15H55 | Link between inflammation and remyelination | Mikael Simons
<i>Munich, DE</i> |
| 15H55 - 16H15 | Remyelination and neuroprotection translational trials: lessons from optic neuritis | Céline Louapre
<i>Paris, FR</i> |
| 16H15 - 16H30 | Closing session and France SEP Prizes | |